Clinical characteristics of PE patients in the study
| Characteristics . | PE patients (N = 436) . |
|---|---|
| Age, mean ± SD, y | 57.9 ± 15.8 |
| Age at the first episode,y | |
| ≤50 | 134 (30.7) |
| >75 | 40 (9.2) |
| Male | 201 (46.1) |
| BMI, kg/m2* | |
| ≤18.5 | 13 (3.0) |
| >18.5-28 | 273 (62.6) |
| >28 | 93 (21.3) |
| With DVT | 277 (63.5) |
| Previous VTE | 87 (20.0) |
| Initial treatment† | |
| NOACs | 352 (80.7) |
| Standard VKA regimen | 81 (18.6) |
| Patients with thrombolytic therapy | 25 (5.7) |
| Characteristics . | PE patients (N = 436) . |
|---|---|
| Age, mean ± SD, y | 57.9 ± 15.8 |
| Age at the first episode,y | |
| ≤50 | 134 (30.7) |
| >75 | 40 (9.2) |
| Male | 201 (46.1) |
| BMI, kg/m2* | |
| ≤18.5 | 13 (3.0) |
| >18.5-28 | 273 (62.6) |
| >28 | 93 (21.3) |
| With DVT | 277 (63.5) |
| Previous VTE | 87 (20.0) |
| Initial treatment† | |
| NOACs | 352 (80.7) |
| Standard VKA regimen | 81 (18.6) |
| Patients with thrombolytic therapy | 25 (5.7) |
Data are presented as n (%) of patients unless otherwise indicated.
BMI, body mass index; VKA, vitamin K antagonist.
Some percentages may not total 100, because 57 patients did not have body mass index data.
Three patients did not receive anticoagulation treatment because of major bleeding in the acute phase or low platelet counts.